Thomas Swift
Assistant Professor in Chemistry at the University of Bradford
Data updated
Research Footprint
Thomas Swift appears in 6 tracked papers (2017–2022), most studied alongside Psilocybin, LSD and Ayahuasca, across Anxiety Disorders, Depressive Disorders and Palliative & End-of-Life Distress.
Most-cited paper: Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis (300 citations).
Frequent co-authors: Roland Griffiths, Gabrielle Agin-Liebes and Stephen Ross.
Background & Research
Dr. Thomas Swift is an Assistant Professor in Chemistry at the University of Bradford. His primary research focuses on functional polymer materials, stimuli-responsive macromolecules, and advanced characterization methods, and he also appears as a coauthor on several psychedelic psychotherapy papers in the clinical literature. At Bradford, he has taught chemistry and helped lead research and industry collaborations in materials science.
Key Impact
He is a coauthor on several qualitative psychedelic-therapy papers that help characterize patient experience, insight, and therapeutic mechanisms in psilocybin and MDMA-assisted treatment.
Collaboration Network
13 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Thomas Swift is associated with.
University of Bradford
The University of Bradford is a public research university in Bradford, West Yorkshire, England. It offers undergraduate and postgraduate programs across a range of disciplines and has a strong focus on research and social inclusion.
View stakeholder →RiverStyx Foundation
Non-ProfitFoundation funding psychedelic science, policy, and education initiatives across the emerging ecosystem.
View stakeholder →Johns Hopkins University
academicThe Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
View stakeholder →